DEERFIELD, Ill.--(BUSINESS WIRE)--TerSera Therapeutics LLC announced today the presentation of new real-world analyses on the treatment patterns of goserelin in women with breast cancer. The data were ...
Goserelin (as acetate) 10.8mg; SC implant. Zoladex is a synthetic decapeptide analogue of GnRH. It acts as an inhibitor of pituitary gonadotropin secretion when administered in the biodegradable ...
In the United States, ZOLADEX ® (goserelin implant) 3.6 mg is the only dosage form approved for use in breast cancer. ZOLADEX 10.8 mg is not approved by FDA for breast cancer. Please see the full ...
AstraZeneca has entered into an agreement with TerSera Therapeutics LLC (TerSera) for the commercial rights to Zoladex (goserelin acetate implant) in the US and Canada. Zoladex is an injectable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results